Zelluna ASA Sustainability Reports
Zelluna ASA is a clinical-stage biopharmaceutical company focused on developing T-cell receptor-guided Natural Killer (TCR-NK) cell therapies to treat solid cancers.
Sector: Professional & technical services
Country: Norway
Exchange: Oslo Børs
LEI: 254900B4VALJZR9TL744
FIGI: BBG00P7CR5K7
4 reports from 2024 to 2025